The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: Part 2-response to therapy, other indications, and future directions

Journal of Nuclear Medicine

Volumn 50, Issue 5, 2009, Pages 738-748

  Lee, Jean H ^a   Rosen, Eric L ^b   Mankoff, David A ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Seattle Radiologists   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

Breast cancer; Continuing education; Molecular imaging; Radionuclide imaging; Response to therapy

Indexed keywords

3' FLUOROTHYMIDINE F 18; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CARBON 11; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; HEAT SHOCK PROTEIN 90; INDIUM 111; IODINE 131; LAPATINIB; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PACLITAXEL; PREDNISONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOSTATIN RECEPTOR; STEROID RECEPTOR; TRACER; TRASTUZUMAB; VINCRISTINE;

ADD ON THERAPY; ADJUVANT THERAPY; ANGIOGENESIS; BONE DENSITY; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CARDIOTOXICITY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DOPPLER FLOWMETRY; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; METASTASIS; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC THERAPY; TOXICITY TESTING; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR VOLUME;

BREAST NEOPLASMS; HUMANS; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 66149144397     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.061416     Document Type: Review

References (150)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Clarke M. Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists' Collaborative Group overview. Ann Oncol. 2006;17(suppl 10):x59-x62.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
4. Doyle DM, Miller KD. Development of new targeted therapies for breast cancer. Breast Cancer. 2008;15:49-56.
5. Lefferts JA, Bartels CL, Tsongalis GJ. Molecular oncology: current trends in diagnostics. Future Oncol. 2008;4:61-70.
6. Mankoff DA. Molecular imaging as a tool for translating breast cancer basic science. Breast Cancer Res. 2008;10(suppl 1):S3.
7. Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2005;89(suppl 1):S9-S15.
8. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986;46:2578-2581.
9. Moskovic EC, Mansi JL, King DM, Murch CR, Smith E. Mammography in the assessment of response to medical treatment of large primary breast tumor. Clin Radiol. 1993;47:339-344.
10. Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J Clin Oncol. 2008;26:786-790.
11. Gralow JR, Zujewski JA, Winer E. Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. J Clin Oncol. 2008;26:696-697.
12. Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat. 2007;105(suppl 1):33-43.
13. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-3685.
14. McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg. 1989;124:21-25.
15. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;2001:96-102.
16. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26:814-819.
17. Mankoff DA, Dunnwald LK. Changes in glucose metabolism and blood flow following chemotherapy for breast cancer. PET Clin. 2006;1:71-81.
18. Benard F, Turcotte E. Imaging in breast cancer: single-photon computed tomography and positron-emission tomography. Breast Cancer Res. 2005;7:153-162.
19. Quon A, Gambhir SS. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol. 2005;23:1664-1673.
20. 18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med. 1989;15:61-66.
21. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101-2111.
22. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27(suppl 1):S215-S229.
23. Bellon JR, Livingston RB, Eubank WB, et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol. 2004;27:407-410. (Pubitemid 39045254)
24. 18F-2-fluoro- 2-deoxy-D-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol. 2004;22:1253-1259.
25. 18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689-1695.
26. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676-1688.
27. 18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366-5372.
28. 18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34:1915-1924.
29. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med. 1996;37:931-938. (Pubitemid 126447124)
30. 18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer. 2002;38:375-379.
31. 18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol. 2004;15:1352-1357.
32. Chen X, Moore MO, Lehman CD, et al. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol. 2004;11:1115-1124. (Pubitemid 39458085)
33. 18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology. Ann Oncol. 2008;19:1573-1577.
34. Maini CL, Tofani A, Sciuto R, et al. Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma. J Nucl Med. 1997;38:1546-1550. (Pubitemid 27443953)
35. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium-99m]-sestamibi scintimammography. Cancer. 1999;85:2410-2423.
36. Dunnwald LK, Hartnett SD, Mankoff DA. Utility and reproducibility of semiquantitative analysis of sestamibi breast images. J Nucl Med Technol. 1997;25:106-109.
37. 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study. Eur J Nucl Med. 2001;28:711-720.
38. 99mTc-sestamibi uptake. Nucl Med Commun. 2005;26:9-15.
39. 99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer. 2005;103:680-688.
40. Mankoff DA, Dunnwald LK, Gralow JR, et al. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nucl Med Biol. 2002;29:719-727.
41. Dunnwald LK, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008;26:4449-4457.
42. Tiling R, Kessler M, Untch M, et al. Breast cancer: monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography. Onkologie. 2003;26:27-31.
43. 99mTc-MIBI. Acta Radiol. 2003;44:284-287.
44. Del Vecchio S, Zannetti A, Aloj L, Salvatore M. MIBI as prognostic factor in breast cancer. Q J Nucl Med. 2003;47:46-50.
45. Ciarmiello A, Vecchio SD, Silvestro P, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 1998;16:1677-1683. (Pubitemid 28234709)
46. Takamura Y, Miyoshi Y, Taguchi T, Noguchi S. Prediction of chemotherapeutic response by technetium 99m-MIBI scintigraphy in breast carcinoma patients. Cancer. 2001;92:232-239.
47. 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response. Breast. 2007;16:262-270.
48. Ugur Y, Sari O, Ugur O, et al. Lack of correlation between Tc-99m-sestaMIBI uptake and cadherin expression in infiltrating ductal breast carcinoma as prognostic indicators. Ann Nucl Med. 2003;17:281-287. (Pubitemid 37012039)
49. 18F]fluoropaclitaxel. Nucl Med Biol. 2007;34:823-831.
50. 18F-fluoropaclitaxel and PET. J Nucl Med. 2006;47:1995-1999.
51. Kedar RP, Cosgrove DO, Smith IE, Mansi JL, Bamber JC. Breast carcinoma: measurement of tumor response to primary medical therapy with color flow Doppler imaging. Radiology. 1994;190:825-830.
52. Bolan PJ, Nelson MT, Yee D, Garwood M. Imaging in breast cancer: magnetic resonance spectroscopy. Breast Cancer Res. 2005;7:149-152.
53. Lehman CD, Schnall MD. Imaging in breast cancer: magnetic resonance imaging. Breast Cancer Res. 2005;7:215-219.
54. Tromberg BJ, Cerussi A, Shah N, et al. Imaging in breast cancer: diffuse optics in breast cancer - detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy. Breast Cancer Res. 2005;7:279-285.
55. Hylton N. MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am. 2006;14:383-389.
56. Li KL, Partridge SC, Joe BN, et al. Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology. 2008;248:79-87.
57. Semple SI, Gilbert FJ, Redpath TW, et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol. 2004;14:2038-2045. (Pubitemid 39481174)
58. 15O-water positron emission tomography blood flow in breast cancer. Acad Radiol. 2008;15:1246-1254.
59. 1H MR spectroscopy - a pilot study at 4 T. Radiology. 2004;233:424-431.
60. 18F]-fluorodeoxyglucose positron emission tomography. J Magn Reson Imaging. 2008;28:420-427.
61. Dehdashti F, Mortimer JE, Trinkaus K, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 2008;113:509-517.
62. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-2803.
63. Kawada K, Murakami K, Sato T, et al. Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. Jpn J Clin Oncol. 2007;37:44-48.
64. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
65. Therasse P, Eisenhauer EA, Buyse M. Update in methodology and conduct of cancer clinical trials. Eur J Cancer. 2006;42:1322-1330.
66. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942-2953.
67. 18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res. 2006;12:6437-6443.
68. 18F-FDG PET. J Nucl Med. 2005;46:1144-1150.
69. 18F]- fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer. 2000;1:156-161.
70. 18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol. 2006;24:3026-3031.
71. Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens RD, Fogelman I. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med. 1988;29:1354-1359.
72. Schneider JA, Divgi CR, Scott AM, et al. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med. 1994;35:1748-1752. (Pubitemid 24346792)
73. Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol. 2004;2:205-220.
74. 18F-fluoride ion PET bone scanning. AJR. 2006;186:1783-1786.
75. Gralow J, Brenner W, Linden H, et al. Changes in tumor metabolism and local bone turnover in patients treated for bone-dominant metastatic breast cancer measured by fluorodeoxyglucose (FDG) and fluoride positron emission tomography (PET) [abstract]. Breast Cancer Res Treat. 2005;94(suppl 1):S261.
76. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375-3379.
77. Stafford SE, Gralow JR, Schubert EK, et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol. 2002;9:913-921.
78. 18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat. 2007;105:87-94.
79. 18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol. 2007;25:3440-3447.
80. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008;247:189-196.
81. Theilmann RJ, Borders R, Trouard TP, et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia. 2004;6:831-837. (Pubitemid 40041502)
82. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol. 2006;33:2-14.
83. Godkar D, Bachu K, Dave B, Megna R, Niranjan S, Khanna A. Comparison and co-relation of invasive and noninvasive methods of ejection fraction measurement. J Natl Med Assoc. 2007;99:1227-1228, 1231-11224
84. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol. 2006;24:5305-5312.
85. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19:420-432.
86. 18F]-D-glucose. Cancer. 1998;82:2227-2234.
87. Esserman L, Kaplan E, Partridge S, et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001;8:549-559. (Pubitemid 32651740)
88. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park). 2005;19(4 suppl 3):7-16.
89. Hayes DF, Miller K, Sledge G. Angiogenesis as targeted breast cancer therapy. Breast. 2007;16(suppl 2):S17-S19.
90. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst. 2005;97:172-187.
91. Kety SS. Basic principles for the quantitative estimation of regional cerebral blood flow. Res Publ Assoc Res Nerv Ment Dis. 1985;63:1-7.
92. Wilson CBJH, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and non-invasive dynamic method. Cancer Res. 1992;52:1592-1597.
93. 2 positron emission tomography measurements of blood flow in patients with intra-abdominal cancers. Clin Cancer Res. 2003;9:6350-6356.
94. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003;44:1806-1814. (Pubitemid 39663314)
95. 15O-labeled water-measured blood flow. J Nucl Med. 2008;49:517-523.
96. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med. 2004;45:1829-1837.
97. Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging. 2003;30:274-280.
98. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J Magn Reson Imaging. 2007;26:235-249.
99. Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging. 2005;30:324-341.
100. Yankeelov TE, Lepage M, Chakravarthy A, et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging. 2007;25:1-13.
101. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769-777. (Pubitemid 46622044)
102. Leach MO, Brindle KM, Evelhoch JL, et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol. 2003;76(special issue 2003):S87-S91.
103. 3 expression in man. Clin Cancer Res. 2006;12:3942-3949.
104. 18F-FDG PET study. Nucl Med Commun. 2007;28:789-797.
105. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500-509.
106. Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007;72:7-25.
107. Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46(12, suppl):2884-2888.
108. Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Tumor receptor imaging. J Nucl Med. 2008;49(suppl 2):149S-163S.
109. Katzenellenbogen J. The pharmacology of steroid radiopharmaceuticals: specific and non-specific binding and uptake selectivity. In: Nunn A, ed. Radiopharmaceuticals: Chemistry and Pharmacology. New York, NY: Marcel Dekker; 1992:297-331.
110. Katzenellenbogen JA, Welch MJ, Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 1997;17:1573-1576.
111. Katzenellenbogen JA. Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med. 1995;36(6, suppl):8S-13S.
112. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45-48.
113. 18F- fluoroestradiol. J Nucl Med. 2008;49:367-374.
114. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766-1774.
115. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-2799. (Pubitemid 46630578)
116. Mezi S, Primi F, Orsi E, Capoccetti F, Scopinaro F, Schillaci O. Somatostatin receptor scintigraphy in metastatic breast cancer patients. Oncol Rep. 2005;13:31-35.
117. 99mTc-depreotide scintigraphy. J Nucl Med. 2006;47:6-13.
118. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312. (Pubitemid 350232263)
119. 18F-FDG PET. J Nucl Med. 2006;47:793-796.
120. 111Indium- trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007;43:2046-2051.
121. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276-2282. (Pubitemid 46630657)
122. 89Zf-trastuzumab for clinical HER2 immunoPET imaging [abstract]. J Clin Oncol. 2007;25:140s.
123. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol. 1995;13:1470-1477.
124. Ishiwata K, Enomoto K, Sasaki T, et al. A feasibility study on L-[1-carbon-11]tyrosine and L-[methyl-carbon-11]methionine to assess liver protein synthesis by PET. J Nucl Med. 1996;37:279-285. (Pubitemid 26150904)
125. 11C]-ACBC) for detecting recurrent brain tumors. Clin Positron Imaging. 1998;1:165-173.
126. Glunde K, Jacobs MA, Bhujwalla ZM. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn. 2006;6:821-829.
127. Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther. 2003;2:497-507.
128. Stanwell P, Mountford C. In vivo proton MR spectroscopy of the breast. Radiographics. 2007;27(suppl 1):S253-S266.
129. 18F]FDG PET in clinical oncology. Lancet Oncol. 2007;8:822-830.
130. Lupu R, Menendez JA. Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators? Endocrinology. 2006;147:4056-4066. (Pubitemid 44274975)
131. Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007;51:1511-1520.
132. Yu EY, Mankoff DA. Positron emission tomography imaging as a cancer biomarker. Expert Rev Mol Diagn. 2007;7:659-672.
133. 11C]Choline as a potential PET marker for imaging of breast cancer athymic mice. Nucl Med Biol. 2002;29:803-807.
134. Tannock IF. Cell proliferation. In: Tannock IF, Hill RP, eds. The Basic Science of Oncology. New York, NY: McGraw-Hill; 1992:154-177.
135. Cleaver JE. Thymidine Metabolism and Cell Kinetics. Amsterdam, The Netherlands: North-Holland Pub. Co.; 1967.
136. Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer. 1995;71:146-149.
137. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am. 2005;43:153-167.
138. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336. (Pubitemid 28512118)
139. 18F-FLT): a pilot study. Eur J Surg Oncol. 2006;32:39-43.
140. 18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339-1347.
141. Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18]fluoro- 3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36-42. (Pubitemid 44201576)
142. 18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2004;31:720-724.
143. Hockenbery D. Defining apoptosis. Am J Pathol. 1995;146:16-19.
144. Blankenberg F, Ohtsuki K, Strauss HW. Dying a thousand deaths: radionuclide imaging of apoptosis. Q J Nucl Med. 1999;43:170-176.
145. van de Wiele C, Lahorte C, Vermeersch H, et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J Clin Oncol. 2003;21:3483-3487. (Pubitemid 46594081)
146. Schoenberger J, Bauer J, Moosbauer J, Eilles C, Grimm D. Innovative strategies in in vivo apoptosis imaging. Curr Med Chem. 2008;15:187-194.
147. 99mTc-annexin V. J Nucl Med. 2005;46:807-815.
148. Morse DL, Galons JP, Payne CM, et al. MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed. 2007;20:602-614. (Pubitemid 47499995)
149. Lee KC, Moffat BA, Schott AF, et al. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res. 2007;13:443-450. (Pubitemid 46225348)
150. McDermott GM, Welch A, Staff RT, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat. 2007;102:75-84. (Pubitemid 46294965)